Tunisie Telegraph: Rasunek offers hope for pancreatic cancer

The U.S. Food and Drug Administration (FDA) has granted emergency approval for the new drug "Rasunke," which contains the active ingredient "Daraxenerasib," to treat patients with metastatic pancreatic cancer, particularly those for whom previous treatments have failed. The medication aims to target the "Ras" protein associated with cancer cell growth, and it appears to significantly extend patients' average survival time, with an average post-treatment lifespan of 13.2 months compared to 6.7 months with traditional chemotherapy. Although the drug is not curative, its arrival in Tunisia requires regulatory and funding procedures, especially given its high cost—around $39,800 per treatment in the United States—raising concerns about healthcare coverage and patients' financial capacity in Tunisia. These developments represent an important step in combating pancreatic cancer, which in Tunisia records approximately 739 cases and 660 deaths annually. It is considered one of the most dangerous cancers due to the difficulty of early detection and the limited effective treatment options in its advanced stages.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل